



THESAN PHARMACEUTICALS ANNOUNCES MR. DANIEL M. BRADBURY AS CHAIRMAN OF THE BOARD OF DIRECTORS JULY 2016

SAN DIEGO, CA. Thesan Pharmaceuticals, a biopharmaceutical company dedicated to the development of novel therapeutics for disorders of the skin, announced today the appointment of Daniel M. Bradbury as Chairman of its Board of Directors, effective immediately.

Mr. Bradbury is a Life Sciences Executive with over 30 years of experience creating and implementing strategies that transform businesses, bring novel medicines to market and maximize shareholder value. He is currently the Managing Member of BioBrit, LLC, a Life Sciences Consulting and Investment firm. Prior to that Mr. Bradbury was the President, CEO and Director of Amylin Pharmaceuticals, a biopharmaceutical company based in San Diego, CA, focused on metabolic diseases. During his 18-year tenure at Amylin, the company launched three first-in-class medicines, for the treatment of diabetes ultimately leading to acquisition of the Company by Bristol-Myers Squibb in August 2012. Before joining Amylin, Dan worked in senior marketing and sales roles for ten years at SmithKline Beecham Pharmaceuticals.

“Dan is a highly successful pharmaceutical executive with a formidable track record of developing and commercializing new medicines and building the companies to support those efforts. All of the Thesan team will greatly benefit from his drug development and commercial experience,” said Gordon Foulkes, the Company’s CEO. “His industry insights and leadership will be invaluable as we move the Company forward.”

Mr. Bradbury currently serves on the Boards of several other life science companies including Biocon Ltd, Corcept Therapeutics, Geron Corporation and Illumina, Inc. He also serves on the Advisory Boards of Investor Growth Capital, BioMed Ventures and UCSD Rady School of Management. “I am honored that the Board and Gordon have asked me to take on this role and I am looking forward to working with them in guiding the development of Thesan’s novel therapeutics to improve outcomes for people with skin disorders and deliver value for Thesan shareholders.”

About Thesan Pharmaceuticals, Inc.

Thesan is a biotechnology company focused on the development and commercialization of novel drugs for the treatment of dermatological conditions.

For more information visit: www.thesanpharma.com

Contact:

J. Gordon Foulkes, Ph.D.
Chief Executive Officer
Thesan Pharmaceuticals, Inc.
Info@ThesanPharma.com